You are responsible for recruiting patients into a new trial of interleukin 2 for cancer therapy. In choosing potential patients, which of the following statements regarding cancer therapy with interleukin 2 (IL-2) is true?
|A||It is a B cell growth factor|
|B||It induces a major response in patients with metastatic breast cancer|
|C||It induces a major response in patients with metastatic colon cancer|
|D||It induces a major response in patients with metastatic melanoma|
(REF DEVITA TEXTBOOK OF SURGICAL ONCOLOGY, 9TH EDN PG 470)
a. Interleukin-2 is a cytokine, which is a protein that acts as a regulator of the body’s immune system, similar to interferon. By giving the patient large doses of this protein, it is hoped that the body’s own immune system will destroy the cancer cells.
b. Interleukin-2 is administered via intravenous (IV) injection as high dose (HD. (usually defined as 600,000 – 720,000 units/kg). Lower dosage IV and subcutaneous IL-2 are also prescribed for kidney cancer, but HD IL-2 is the only regimen that has FDA approval.
c. HD IL-2 is highly toxic, and it is administered for one week.
d. Patients must have a creatinine level < 1.5, have no uncontrolled heart arrhythmia, and have good pulmonary and liver function.